Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2008 1
2009 1
2010 2
2011 1
2012 2
2014 2
2015 3
2016 1
2017 2
2019 1
2021 1
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells.
Russo M, Panini N, Fabbrizio P, Formenti L, Becchetti R, Matteo C, Meroni M, Nastasi C, Cappelleri A, Frapolli R, Nardo G, Scanziani E, Ponzetta A, Bani MR, Ghilardi C, Giavazzi R. Russo M, et al. Among authors: ghilardi c. Oncoimmunology. 2023 Aug 1;12(1):2239035. doi: 10.1080/2162402X.2023.2239035. eCollection 2023. Oncoimmunology. 2023. PMID: 37538353 Free PMC article.
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Dellavedova G, Decio A, Formenti L, Albertella MR, Wilson J, Staniszewska AD, Leo E, Giavazzi R, Ghilardi C, Bani MR. Dellavedova G, et al. Among authors: ghilardi c. Cancer Res Commun. 2023 Mar 27;3(3):489-500. doi: 10.1158/2767-9764.CRC-22-0423. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 36994441 Free PMC article.
PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer.
Ghilardi C, Moreira-Barbosa C, Brunelli L, Ostano P, Panini N, Lupi M, Anastasia A, Fiordaliso F, Salio M, Formenti L, Russo M, Arrigoni E, Chiaradonna F, Chiorino G, Draetta G, Marszalek JR, Vellano CP, Pastorelli R, Bani M, Decio A, Giavazzi R. Ghilardi C, et al. Cancer Res. 2022 Apr 1;82(7):1423-1434. doi: 10.1158/0008-5472.CAN-21-1223. Cancer Res. 2022. PMID: 35131872 Free PMC article.
A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing.
Angiolini F, Belloni E, Giordano M, Campioni M, Forneris F, Paronetto MP, Lupia M, Brandas C, Pradella D, Di Matteo A, Giampietro C, Jodice G, Luise C, Bertalot G, Freddi S, Malinverno M, Irimia M, Moulton JD, Summerton J, Chiapparino A, Ghilardi C, Giavazzi R, Nyqvist D, Gabellini D, Dejana E, Cavallaro U, Ghigna C. Angiolini F, et al. Among authors: ghilardi c. Elife. 2019 Mar 4;8:e44305. doi: 10.7554/eLife.44305. Elife. 2019. PMID: 30829570 Free PMC article.
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, Baakza H, Wilson J, Ghilardi C, Cadogan EB, Giavazzi R, Bani MR. Anastasia A, et al. Among authors: ghilardi c. Mol Cancer Ther. 2022 Apr 1;21(4):555-567. doi: 10.1158/1535-7163.MCT-21-0420. Mol Cancer Ther. 2022. PMID: 35149547
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R. Bizzaro F, et al. Among authors: ghilardi c. J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x. J Hematol Oncol. 2021. PMID: 34742344 Free PMC article.
Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Ceruti T, Frapolli R, Ghilardi C, Decio A, Dellavedova G, Tommasi S, Zucchetti M, Mangoni AA. Ceruti T, et al. Among authors: ghilardi c. Molecules. 2023 Dec 13;28(24):8056. doi: 10.3390/molecules28248056. Molecules. 2023. PMID: 38138547 Free PMC article.
22 results